APOL1 Kidney Disease: What Every Black American Should Know

Every year, thousands of Black Americans are diagnosed with kidney disease — and a significant number never learn the real reason why. They are told it is high blood pressure, or diabetes, or simply bad luck. Sometimes that is true. But for many patients, the answer lies in something they were born with: a gene variant called APOL1.

Today is APOL1 Awareness Day, and as a nephrologist who cares deeply about health equity, I want to share what this gene means, who is at risk, and — most importantly — what you can do right now.

What Is APOL1 — And Why Does It Matter?

APOL1 stands for Apolipoprotein L1. It is a gene we all carry, but two specific variants — called G1 and G2 — are found almost exclusively in people of West African descent. These variants exist because, thousands of years ago, they protected people against African sleeping sickness, a deadly parasitic infection.

KEY POINT

Evolution solved one problem — and created another. The same variants that once protected against a deadly parasite can, under the right conditions, injure the kidneys.

When a person inherits two copies of these risk variants (one from each parent), the APOL1 protein can begin to injure the kidney's filtering cells — called podocytes. Over time, this leads to protein leaking into the urine and scarring in the kidney — a condition called FSGS (focal segmental glomerulosclerosis) — and eventually, kidney failure.

Who Is at Risk? The Numbers Are Striking.

APOL1 kidney disease primarily affects people of West African ancestry, including most African Americans. Here is what the data show:

Statistic	Detail
Carry ≥1 risk variant	~50% of African Americans
Carry 2 risk variants (high-risk)	~13% of African Americans
People affected worldwide	Over 70 million
FSGS risk (vs. non-carriers)	Up to 17× higher
HIV-associated nephropathy risk	Up to 89× higher
Typical disease onset	Before age 50
Earlier dialysis vs. non-carriers	~10 years earlier

Important: Having two risk variants does not guarantee kidney disease. Only about 15–20% of high-risk carriers will develop significant CKD in their lifetime. But certain triggers can tip the balance.

What Triggers APOL1 Kidney Disease?

Think of APOL1 variants as a loaded gun. The trigger is usually a "second hit" — an outside stressor that activates the gene or injures already-vulnerable podocytes.

• HIV infection (APOL1 carriers have up to 89× higher risk of HIV-associated kidney disease)

• COVID-19 infection

• Lupus flares

• Interferon-based medications — used for hepatitis C/B, multiple sclerosis, some blood cancers

• Certain IV bone medications such as pamidronate (Aredia)

• JAK inhibitor medications and some cancer immunotherapies

• Sustained inflammation from any cause

DR. VYAS SAYS

If you are of African descent and need any of these medications, tell your doctor about your family history of kidney disease. That one conversation could change your care plan.

What Are the Warning Signs?

APOL1 kidney disease is often silent until it is advanced. The earliest signs can be subtle and easy to dismiss:

• Foamy or bubbly urine — this is protein leaking from the kidneys

• Swelling in the legs, ankles, or around the eyes

• High blood pressure that is difficult to control

• Fatigue without a clear cause

• An abnormal kidney function test (creatinine, eGFR) found on routine bloodwork

If you or a family member of African descent has any of these signs — especially without diabetes — please ask your doctor about a kidney evaluation.

Frequently Asked Questions

Q: Should I get tested for APOL1?

This is a question I get often, and the honest answer is: it depends. Right now, major kidney disease organizations like KDIGO do not recommend routine genetic screening for the general population. But testing does make sense in certain situations:

• You are of African ancestry with protein in your urine and no diabetes

• You have been diagnosed with FSGS or unexplained kidney disease

• You are being evaluated as a living kidney donor

• You have a family history of early kidney failure (before age 60)

• You may be eligible for a clinical trial for targeted APOL1 therapy

  
  

Genetic counseling is recommended before testing. A positive result carries real emotional weight and complex implications — especially given incomplete penetrance.

Q: How is APOL1 kidney disease treated?

There is currently no FDA-approved treatment specifically targeting APOL1 kidney disease. What we do have are effective tools for slowing progression:

• ACE inhibitors or ARBs — blood pressure medications that also protect the kidneys and reduce proteinuria. These are the cornerstone of treatment.

• SGLT2 inhibitors (empagliflozin, dapagliflozin) — originally developed for diabetes, now proven to slow kidney disease progression broadly.

• Tight blood pressure control — critical, since hypertension significantly accelerates APOL1 kidney disease.

• Removal of second-hit triggers — stopping an offending medication or treating HIV can sometimes lead to partial or full recovery.

  
  

Note: Steroids and conventional immunosuppressants have limited efficacy in APOL1-driven FSGS and carry significant side effects. Knowing your genotype can genuinely change the treatment approach.

Q: Is there anything new on the horizon?

Yes — and this is genuinely exciting. The research landscape for APOL1 kidney disease is moving faster than almost any other area of nephrology. Three therapies are in active clinical development:

Therapy	How It Works	Stage	Key Result
Inaxaplin (VX-147)	Blocks APOL1 protein's toxic channel activity in podocytes	Phase 2–3 Trial (NCT05312879)	47.6% reduction in proteinuria at 13 weeks
APOL1 ASO (IONIS-APOL1Rx)	Reduces the body's production of APOL1 mRNA/protein	Preclinical / Early Clinical	Prevented proteinuria in transgenic mouse models
Baricitinib (JAK1/2 inhibitor)	Blocks the signaling pathway that turns on APOL1 gene expression	Phase 2 — JUSTICE Trial (NCT05237388)	Enrolling; 41% UACR reduction seen in related CKD model

WHAT THIS MEANS

If any of these therapies reach FDA approval, APOL1 genotyping will likely become standard practice — because you will need to know your genotype to qualify for treatment. Getting tested when appropriate puts you ahead of the curve.

Q: What if I am considering donating a kidney?

APOL1 genotype matters significantly here. Kidneys from deceased donors with two APOL1 risk variants fail 2–4 times more rapidly after transplant. If you are of African descent and are being evaluated as a living kidney donor, please discuss APOL1 genotyping with your transplant team. This information protects both you and your recipient.

A Message for This Awareness Day

Awareness is the first step toward equity.

APOL1 kidney disease is not a disease of bad choices or poor compliance. It is a genetic predisposition carried by millions of Black Americans — disproportionately burdening a community that already faces significant health disparities.

My mission at Kidney MD is to make sure that every patient — regardless of background — has access to the knowledge and care they deserve. If you have questions about your kidney health, your family history, or whether APOL1 testing is right for you, I am here.

— Dr. Ritu R. Vyas, MD | KidneyMD LLC | Catonsville, MD | (443) 380-0120 | kidneymd.net

Concerned about your kidney health?

Schedule a consultation at Kidney MD in Catonsville, MD.

📞 (443) 380-0120   |   🌐 kidneymd.net

Disclaimer: This post is for educational purposes only and does not constitute medical advice. Please consult your physician or a board-certified nephrologist for personalized guidance.